Connect with us

Cannabis News

More Than 200,000 People Were Arrested For Marijuana In The U.S. Last Year, FBI Data Shows

Published

5 months ago

on

Nearly 188,000 people were arrested in the US last year for possession of marijuana, according to the FBI’s latest annual crime report, and another 16,000 for selling or growing cannabis. However, these figures are underestimated given the inconsistencies in federal data and questions about the agency’s methodology.

The entire 2024 data set is based on more than 14 million crimes reported to the Uniform Crime Reporting (UCR) Program, which is used to document and analyze national crime trends. The report covers 95.6 percent of the U.S. population, the FBI said.

This latest data shows that cannabis-related crimes decreased slightly compared to 2023, from 200,306 possession arrests to 187,792 in 2024 and from 16,844 sales or manufacturing arrests to 16,244.

Advocates see the reduction as a reflection of the success of the legalization movement spreading at the state level, but also point out that marijuana is still the most commonly arrested illegal substance in Americans’ “war on drugs.”

“While the total number of marijuana-related arrests has dropped nationwide in recent years, it’s clear that marijuana-related charges are still a major driver of drug war enforcement in the United States,” NORML Deputy Director Paul Armentano told Marijuana Moment.

In the new report, 27 percent of all drug possession arrests were for marijuana, more than for any other substance specifically listed.

Because not all agencies provide complete data for reporting periods, the FBI explained that the bureau calculates estimated crime numbers by essentially extrapolating “using the data provided following a standard estimation procedure.” In terms of total arrests reported for the category called “drug/narcotics,” for example, the FBI said there were 831,446 arrests.

At the same time, frustrations over the inconsistency of the FBI the data Reports of cannabis and other drug arrest trends have been maintained. Different sections of the report report different numbers for seemingly similar categories of crime.

An FBI chart says there were 1,413,223 “drug/narcotics crimes” in 2024. Another uses the figure of 1,577,175 in the same heading. A third total is 1,870,804.

Another section says there were 822,488 arrests for drug abuse violations in 2024, about 12 percent of the estimated 7.5 million arrests nationwide.

The FBI data also shows trends over time, indicating that 1,055,013 drug-related charges were filed in 2015 and 600,400 drug-related charges were filed in 2024, a decrease of about 43 percent, although it is unclear how much of the change is due to changes in the agency’s arrest practices and methods. State drug laws over the past decade.

In terms of controlled substance seizures in 2024, the agency said 386,540 cases of marijuana were seized out of a total of 1,072,704 drug seizures, about 36 percent of enforcement actions.

Lawmakers, researchers, and the media rely on FBI arrest data to understand and contextualize law enforcement trends. Not only do inconsistencies affect the public’s understanding of crime and law enforcement, but also how policies are developed and implemented.

The bureau was tipped off to the FBI’s alleged marijuana bug in May 2022, when Eric Sterling, a longtime drug reformer and former congressional staffer, said he discovered the presence of a Maryland police department. reporting cannabis possession citations issued under the state’s decriminalization law at the time as arrests As part of a data sharing partnership with the FBI.

Because other state and local law enforcement agencies don’t seem to report cannabis citations as arrests, Sterling reasoned, the inconsistent practice can significantly skew the FBI’s annual reports, making it harder to draw reasonable policy conclusions from the data.

In 2023—14 months after Sterling sent the query—the office finally responded. However, instead of addressing the apparent issue, the Department of Justice’s (DOJ) Office of the Inspector General’s Investigations Division said it had determined that “the issues you raised are more appropriate for consideration by another DOJ office.” He referred the inquiry to the FBI’s investigative division.

The FBI’s report on cannabis enforcement is also at risk because local and state police are not required to share data to inform the agency’s annual report, which is It provides a comprehensive view of law enforcement activities. The agency itself says that some data may not be comparable to previous years, due to varying levels of participation over time.

—
It’s Marijuana Moment tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25 a month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Meanwhile, the Drug Enforcement Administration (DEA) said in a recent filing The process of reorganizing marijuana is at a standstill in the phase it has been in for monthsdespite the agency head’s prior commitment to senators that he would prioritize the issue if confirmed for the role.

President Donald Trump said in August that he planned to make a decision on his proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA) within weeks.

The overhaul would not legalize marijuana, however, so it remains to be seen how the reform might affect arrest rates reported in future FBI annual reports.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Cannabis products recalled due to “unreliable” tests

Published

16 hours ago

on

March 3, 2026

By











New York State’s Office of Cannabis Management (OCM) has recalled several cannabis products after finding that reported results from a testing laboratory were “unreliable.”

OCM says it has found a total of 54 product lots that tested false positive for Aspergillus, the mold that causes disease. According to OCM, another batch of product had incorrect results for the heavy metal cadmium.

“When test results are inaccurate or unclear, product safety and, in turn, the safety of New York State consumers cannot be guaranteed,” said OCM Executive Deputy Director of Licensing, Enforcement and Laboratories Stephen Geskey. “It’s not a risk OCM is willing to take.”

This information comes from an audit of inspections and records conducted by Keystone State Testing New York between December 2025 and January 2026. According to OCM, there have been no reports of the effects of consuming any of the products.

Read more at News 10










Continue Reading

Cannabis News

Virginia House And Senate Lawmakers Advance Marijuana Sales Legalization Bills Toward Governor’s Desk

Published

16 hours ago

on

March 3, 2026

By

The march to legalize the sale of recreational marijuana in Virginia continues, with the full House of Representatives and a Senate committee advancing a pair of bills to create a regulated adult cannabis market in the commonwealth.

The House on Tuesday approved the second reading of the cannabis sale bill passed by the Senate, giving it the chance to pass it definitively in the chamber. Earlier, a House measure moved through the Senate Finance and Appropriations Committee on a 10-5 vote, sending the measure back to the floor for consideration.

Both chambers’ marijuana-sale proposals aim to give adults a legal way to buy cannabis, legalizing both state possession and home cultivation in 2021, though there are key differences between them.

Bicameral measures—HB 642 and SB 542—Recently changed to allow micro business licensees to cultivate, process or conduct retail sales at two locations instead of one, as long as they are within 10 miles of each other and operate under common ownership and control.

Lawmakers also revised the legislation to clarify that current medical cannabis businesses would only be able to grow cannabis indoors, including in secure greenhouses with a total hood of 70,000 square feet. The amendments also would not allow additional marijuana licenses with “dual-use privileges” beyond medical licenses.

Finally, the measure’s conversion fee structure was revised to pay current medical marijuana companies the privilege of dividing the adult-use market into three parts.

There are some key differences between the House bills that still need to be ironed out — related to the start date of legal sales and cannabis tax rates — before a final product can be delivered to the governor’s desk.

Here are the key details of Virginia’s marijuana sales legalization legislation, SB 542 and HB 642:

  • Adults would be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products, as determined by regulators.
  • The House bill sets a statewide sales date of Nov. 1, 2026, while the Senate measure would allow it to begin on Jan. 1, 2027.
  • The Senate bill would impose a 12.875 percent excise tax on cannabis products, in addition to a 1.125 percent state sales tax and a mandatory 3 percent local tax. The House measure would apply a 6 percent excise tax, as well as a 5.3 percent retail sales and use tax, allowing municipalities to impose a 3.5 percent local tax.
  • Under the House bill, the Virginia Cannabis Control Authority would oversee licensing and regulation of the new industry, while the Senate legislation calls for a new combined Alcoholic Beverage and Cannabis Control Authority.
  • The House bill calls for the proceeds to be allocated to a new Cannabis Equity Reinvestment Fund (60 percent), early childhood education (10 percent), the Department of Behavioral and Developmental Health Services (25 percent) and public health initiatives (5 percent). The Senate proposal, on the other hand, would put 30 percent into the capital reinvestment fund, 40 percent for early childhood education, 25 percent for the department of behavioral and developmental health services and 5 percent for public health initiatives.
  • Local governments could not allow marijuana companies to operate in their area.
  • Delivery services would be allowed.
  • Serving sizes would be limited to 10 milligrams of THC, with no more than 100 mg of THC per package.
  • Existing medical cannabis operators could enter the adult-use market if they pay a license conversion fee set at $15 million in the Senate bill and $10 million in the House measure.
  • Cannabis businesses should implement peaceful labor agreements with their employees.
  • A legislative committee would direct the addition of local consumer licenses and micro-enterprise cannabis event permits that would allow licensees to hold sales at farmers markets or pop-up locations. The Virginia Alcoholic Beverage Control Authority would also investigate the possibility of involvement in marijuana regulation and enforcement.

Both the Virginia House and Senate Last month, he took action on multiple marijuana bills during a major deadline—accept proposals to legalize the sale of cannabis, provide a way to punish previous marijuana convictions and allow access to medical cannabis for seriously ill patients in hospitals.

As for the Senate marijuana sales bill, members recently clashed in committee over amendments to the body version that would add new penalties for illegal cannabis activity.

The amendments in the Judiciary Committee’s case included penalties for consumers who purchase from unlicensed sources, recriminalizing possession and sale of cannabis by those under 21, making it a Class 1 felony for a first offense and a felony punishable by a mandatory prison sentence for a second offense. As revised, the bill would also increase the penalty for unlicensed cultivation to a felony with up to five years in prison and make it a felony to transport cannabis with the intent to distribute it across state lines.

But the Finance and Appropriations Committee backed down the amendments last month, sending a letter to senators under pressure from a coalition of advocacy groups. saying that they undermined the “intent” of the legislation and “the will of the people” by adding criminal penalties to certain cannabis-related activities.

In general, both chambers’ commercial sales bills have largely aligned with recommendations released by the legislature in December. Joint Committee to Oversee the Transition to the Commonwealth Retail Cannabis Market.

Meanwhile, some members of the GOP have aligned ideologically with their Democratic colleagues throughout this legislative process, breaking with the majority of their caucus. in favor of creating a regulated market for adults to buy cannabis.

Since legalizing cannabis ownership and home cultivation in 2021, Virginia lawmakers have been working to establish a commercial marijuana market– Only for those efforts to stall under former Gov. Glenn Youngkin (R), who twice vetoed measures sent to his desk by the Legislature.

Governor Abigail Spanberger (D), for her part, supports legalizing the sale of marijuana to adults..

Meanwhile, members of the Virginia House and Senate advanced a pair of bills Monday, with amendments that provide a pathway to resentencing for people with prior marijuana convictions.

Members of the Senate and House Judiciary Committees approved alternate versions of the opposite chamber’s reform bill on Monday, setting the stage for bicameral negotiations as the measures move through the legislative process.

Legislation introduced in both chambers would create a process to consider changing the sentences under which people incarcerated or on community custody for certain felonies involving the possession, manufacture, sale or distribution of marijuana could receive an automatic trial.

Separately last month, the Virginia House patients passed a bill to allow the use of medical marijuana in hospitals. It would require health care facilities to implement policies “to address the situation in which an eligible patient is authorized to use medical cannabis.”

The Senate passed various pieces of legislation use of medical cannabis in healthcare facilities last month

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Meanwhile, the Virginia House passed the bill earlier this month Protecting the rights of parents who use marijuana by complying with state laws.

Del. According to the proposal by Nadarius Clark (D), a parent or guardian’s own use of cannabis “shall not serve as a basis for a finding of abuse or neglect of a child unless other facts establish that its possession or consumption causes or produces physical or mental injury to the child.”

“A person’s legal possession or consumption of substances permitted (under state marijuana law) shall not serve as a basis for limiting custody or visitation unless other facts establish that such possession or consumption is not in the best interest of the child,” reads the text of HB 942.

Separately, the Virginia Department of Labor and Industry has published a new defining workplace protections for cannabis users.

Photo by Chris Wallis // Side Pocket Images.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Swiss company launches nationwide price comparison tool for cannabis

Published

2 days ago

on

March 2, 2026

By











Evidena Care AG is one of the leading Swiss telemedicine platforms and specialized medical practices for medical cannabis. The company currently supports more than 2,000 patients across the country. Under the direction of Dr. Nicolai Berardi and two other specialist doctors, Evidena Care has focused on evidence-based, responsible and patient-centered treatment for the past two years.

Now, Evidena Care is launching a nationwide online comparison portal for medical cannabis products. The platform is designed for patients who already have a valid medical prescription and want a clear and reliable view of the market. For the first time in Switzerland, patients can directly compare products and prices from the country’s largest pharmacies in one place.

Medical cannabis plays an essential role in the treatment plans of many patients. At the same time, prices can vary significantly between pharmacies, even when the products contain the same levels of active ingredients. As these costs are often not covered by health insurance, or only partially covered, many patients have a heavy financial burden. The new portal addresses this issue by bringing transparency to a market that until now has been difficult to navigate.

The platform provides an overview of available products and dosages, clearly lists the active ingredient content, such as THC and CBD levels, and displays the current prices of leading Swiss pharmacies. Patients can directly compare options and make informed decisions that help optimize their therapy costs, without compromising medical guidance.

“Patients should not be victims of non-transparent pricing structures,” says Dr. Nicolai Berardi, CEO of Evidena Care AG. “We are creating transparency with our comparison portal, strengthening the self-responsibility of those affected and promoting fair competition in the interests of patients.”

The portal is only for people with a valid prescription. It serves as a true information tool and supports cost optimization in an existing therapy supervised by a physician.

For more information:
Evidena Care AG
Email: (email protected)
https://evidena.care/










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media